1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Adcomm Open Public Hearings Have Become Too Sponsor-Driven – US FDA's Pazdur

 
• By Sue Sutter

Oncology Center of Excellence Director Richard Pazdur says he would like to see more diverse views during the OPH session, not just individuals curated by the sponsor to present ‘a very positive picture’ of the drug. An upcoming ODAC meeting will have everyone in-person except the OPH speakers, public and press.

Organic logo
FDA's Richard Pazdur bemoaned the loss of the organic nature of advisory committee open public hearings. • Source: Shutterstock

The US Food and Drug Administration's Richard Pazdur would like to see the open public hearing portion of advisory committee meetings revert to a more neutral forum not dominated by sponsor-driven support.

“We really would like to have a more constructive public hearing” at Oncologic Drugs Advisory Committee meetings, Pazdur, director of the Oncology Center of Excellence, said during a 5 April fireside chat at a partnering event held ahead

More from US FDA Performance Tracker

More from Regulatory Trackers